A new article on the Forbes website poses the question, ‘Could drug-resistant bacteria cause the next pandemic?’ and highlights the need to fund and incentivise the discovery and development of new antibacterial drugs to tackle this threat.
Neil Clark, CEO of Destiny Pharma has been interviewed by Andy Edmond from Equity Development, the UK’s leading independent investment research company. Please follow the link below to watch the interview:
Twenty-three leading biopharmaceutical companies have joined forces to invest $1 billion in a fund to develop new antibiotics, which are needed urgently to fight the worldwide rise in antimicrobial-resistant superbugs. The AMR Action Fund, aims to bring 2-4 new antibiotics to patients by 2030. Through the AMR Action Fund, pharmaceutical companies will join forces with philanthropies, development banks, and multilateral organizations to strengthen and accelerate antibiotic development. The Fund will focus on urgent public health needs. It will provide much needed financial resources, as well as important technical support to help biotech companies bring novel antibiotics to patients.
Destiny Pharma CEO Neil Clark said ”We welcome this significant new fund supporting novel drug development addressing AMR. The world needs new antinfective drugs and Destiny Pharma is one of the few biotech companies dedicated to this global clinical need. The new pharma backed fund is clear recognition of the clinical need and is the latest in a series of new initiatives from regulators, governments and healthcare investors to support innovation that addresses AMR”.
Destiny Pharma CEO Neil Clark has been interviewed for an Endpoints News article published on the 7th April discussing what the coronavirus pandemic means for the field of antibiotics. To read more please see here
Destiny Pharma plc
(“Destiny Pharma” or “the Company”)
Destiny Pharma XF Drug platform data to be presented at EuroBiofilms
Data part of collaboration with Cardiff University to identify safe and efficacious compounds with a reduced anti-microbial resistance profile
Brighton, United Kingdom – 2 September 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs which address the global problem of anti-microbial resistance (AMR), announces that data from its collaboration, ‘Evaluation of XF Drugs as Antibiotic Resistance Breakers’, with Cardiff University is being presented at the EuroBiofilms conference, in Glasgow, 3-6 September 2019.
The poster, entitled ‘Evaluation of the novel XF Drugs: Potent antibacterial drugs with Twin Mechanisms of Action’, is being presented by Dr Emma Board-Davies, Post-Doctoral Research Associate, School of Pharmacy and Pharmaceutical Sciences, Cardiff University. The data looks at the potency of Destiny Pharma’s product platform, including XF-73, XF-70 and DPD-207, against a range of the critical, infection causing bacteria.
The research programme, ‘Evaluation of XF Drugs as Antibiotic Resistance Breakers,’ is a two-year project examining the use of the Company’s novel XF drugs to prevent, control and eradicate life threatening bacteria or “superbugs” without generating resistance. It is funded by the UK-China AMR grant fund set up by Innovate UK and the Department of Health and Social Care with the Chinese Ministry of Science and Technology at the beginning of 2019.
EuroBiofilms provides participants with a valuable forum for a fruitful scientific exchange in the field of microbial biofilms. An opportunity for scientists, clinicians and industry partners with an interest in biofilm-related problems to exchange novel information on clinical, environmental and basic elements of microbial biofilms.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
Simon Conway / Victoria Foster Mitchell
+44 (0) 20 3727 1000
finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash /Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines from its XF Platform that represent a new approach to the treatment of infectious disease. The company’s lead programme is undergoing a Phase 2b clinical trial and is targeting the prevention of post-surgical hospital infections including MRSA. The XF drug candidates are being developed for the prevention and treatment of life-threatening infections caused by antibiotic‑resistant bacteria, often referred to as “superbugs”. Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit www.destinypharma.com
XF-73 is a synthetic anti-microbial active against all tested Staphylococcus aureus strains, including drug‑resistant strains. By acting via a cell-surface mechanism it affects the bacterial membrane permeability and integrity, leading to cell death. XF-73 has already been through seven successful Phase I/II clinical trials showing it is safe and delivers a rapid antibacterial action. In standard microbiology studies XF drugs have demonstrated a unique no/low resistance profile that means that XF compounds have the potential to deliver novel drugs that are clearly differentiated from traditional antibiotics where resistance limits their utility.
XF-73 is indicated for the prevention of post-surgical staphylococcal infections. In the US, there are approximately 40 million surgeries per annum alone where the patient is at risk of a post-surgical infection. However, within this large population there are particular groups who are at an even higher risk of infection due to the nature of their surgery or the procedures and/or their specific hospital environment in which they are treated. These higher risk surgical procedures include cardiovascular, orthopaedic and other complex surgeries. Destiny Pharma estimates that this totals approximately 14 million US surgeries per year, with this figure set to rise within the context of an ageing population.
Information about a recent change can be found here.
Destiny Pharma has won Deal of the Year at the Insider South East Dealmakers Awards 2018, held on 1 February 2018 at The Copthorne in Gatwick, UK.
Now in its twelfth year, the Dealmakers awards recognise the region’s top deals and advisory companies over the course of the last 12 months. The Deal of the Year award follows Destiny Pharma’s flotation on AIM in September 2017, raising £15.3m to accelerate the clinical development of its lead product, XF-73, and XF drug development platform.
Neil Clark, Chief Executive Officer of Destiny Pharma, commented:
“We are very pleased to be awarded this award for our successful placing and admission to trading on AIM in September of last year, which marked a major milestone for Destiny Pharma. We continue to advance the clinical development of our lead product, XF-73, and our proprietary XF drug development platform to offer a novel way of tackling the global problem of anti-microbial resistance.”
A high-profile consortium, DRIVE-AB, has published a study in the wake of this announcement recommending broad incentives to promote antibiotic innovation and the sustainable use of the resulting, novel antibiotics to combat antibiotic resistance.
Neil Clark, Chief Executive Officer of Destiny Pharma, commented: “Antibiotic resistance is a major global concern and DRIVE-AB’s study outlines additional support that is needed to assist drug companies in combating this issue. These incentives aim to expand the number of companies such as Destiny Pharma operating in this area and to support the expansion of the development of new treatments.”
The study, titled Revitalizing the Antibiotic Pipeline: Stimulating Innovation while Driving Sustainable Use and Global Access, was produced by an international group made up of 23 partners from big pharma, academic institutions and public health organisations. The complementary measures laid out in the study cover 30 incentives on how to drive antibiotic innovation. Three primary solutions include:
- Market entry reward for truly innovative antibiotics: A $1 billion reward per antibiotic globally, in addition to sales revenue, could quadruple novel antibiotics over 30 years
- Maximised antibiotic R&D environment: An increase of $300 million, or approximately 50%, in government grant funding and R&D coordinators are need to foster collaboration and fundamental research
- Long term governance: The G20, through their recently announced Global R&D Collaboration Hub, should implement a focused investment strategy and facilities the above two points